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Abstract. There has been an increase in the incidence of anal 
cancer in the past two decades, with squamous cell carcinoma 
(SCC) being the most frequent histological type identified. 
Among the risk factors, high-risk human papillomavirus 
(HPV) infection is the most pervasive. Raf kinase inhibitor 
protein (RKIP) is expressed in a number of normal human 
tissues and previous studies have demonstrated the prognostic 
value of the loss of RKIP expression in several gastrointes-
tinal tumors. Therefore, the present study aimed to evaluate 
the clinical implications of RKIP expression in a series of 
neoplastic lesions of the anal canal. The resected tumors of 
48 patients [8 high-grade intraepithelial lesions (HSILs), 
14 adenocarcinomas and 26 squamous cell carcinomas (SCCs)] 
were immunohistochemically evaluated for RKIP expression, 
and the results were correlated with clinicopathological data. 
The results identified a decreased 5‑year overall survival rate 
in patients with adenocarcinoma (40.8%) compared with 
patients with SCC (76.7%), and a decreased 5‑year disease‑free 
survival rate in patients at clinical stages III/IV (37.3 vs. 62.5 
and 82.6% for clinical stages 0 and I/II, respectively). Low 
RKIP expression was revealed in 62.5% of HSILs, 88.5% 
of SCCs and 100.0% of the adenocarcinomas. High RKIP 
expression was associated with patient ethnicity (37.5% in 
non‑Caucasians vs. 7.5% in Caucasians) and patient age 
(33.3% in younger patients vs. 0.0% in older patients). Finally, 
high RKIP expression was correlated with HPV16 infection 
status (40% in HPV- vs. 5.3% in HPV+ patients). A correlation 
was identified between high RKIP expression and lesions with 
a generally improved prognosis, such as those diagnosed in 
younger patients, in situ lesions and lesions of lower clinical 
grades; there was also a negative correlation between high 
RKIP expression and HPV16 positivity in patients.
Introduction
Though considered rare, anal cancer incidence has increased 
in the last 20 years in the USA (1), with an estimated 8,080 new 
cases and 1,080 associated mortalities in 2016 (2). The most 
frequent histological type is squamous cell carcinoma (SCC), 
responsible for ~95% of anal tumors (3). The risk factors for 
anal cancer include human papillomavirus (HPV) infection, 
immunodeficiency, immunosuppression and tobacco smoking; 
however being HPV+ has been demonstrated to be the most 
important factor (4,5). Among the distinct HPV types, HPV16 
is the most frequently identified in anal SCC (6) and may 
cause infected cells to progress from intraepithelial neoplasia 
to high‑grade dysplasia, and finally to invasive cancer (5,7). 
Additionally, an increased prevalence of infection with 
high-risk HPV (HR-HPV) has been identified in the anal 
canals of women with HPV-associated pathologies, including 
cancer of the vulva, vagina and cervix, compared with in 
women without these HPV-associated pathologies (8).
It has been revealed that HR-HPV infections, particularly 
with concomitantly elevated expression of the viral gene 
products E6 and E7, are involved in cell cycle entry and cell 
proliferation (9,10). E7 protein binds retinoblastoma protein, 
inducing its degradation and aberrant cell cycle progression by 
upregulating p21 and p16 (11). E6 protein is involved in several 
oncogenic events, leading to p53 degradation, nuclear factor 
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(NF)‑κB pathway activation under hypoxic conditions, and 
the upregulation of human telomerase reverse transcriptase, 
which promotes cell immortalization (11). A previous study 
identified NF‑κB as an independent predictor of disease-free 
survival (DFS) in patients treated with chemotherapy (12).
Raf kinase inhibitor protein (RKIP) is described as an NF‑κB 
suppressor (13), an inhibitor of the Raf/mitogen-activated 
protein kinase/extracellular signal-regulated kinase (ERK) 
kinase (MEK)/ERK signaling pathway (14), and a regulator of 
G protein-coupled receptors (15). RKIP is expressed in several 
normal human tissues (16), and previous studies have demon-
strated the prognostic value of the loss of RKIP expression in 
various gastrointestinal tumors, including colorectal cancer, 
gastrointestinal stromal tumors and gastric cancer (17-19). 
To date, only a limited number of molecular biomarkers 
have been identified that are able to predict treatment 
outcomes or response in anal cancer, including HPV infec-
tion, p16 protein expression (20,21), and the overexpression 
of multidrug resistance-associated protein 1, excision repair 
cross-complementation group 1 and thymidylate synthase (22). 
KRAS proto-oncogene (KRAS) mutations, which are predictors 
of patient outcomes (23) in colorectal tumors, were identified 
at a low frequency in tumors of the anal canal (24). Therefore, 
the aim of the present study was to evaluate the clinical impli-
cations of RKIP expression using immunohistochemistry in 
a series of invasive lesions (SCCs and adenocarcinomas) and 
in situ lesions [high-grade squamous intra-epithelial lesions 
(HSILs)] of the anal canal.
Materials and methods
Patients and samples. The resected tumors of 48 patients 
with anal cancer (27 female, 21 male), diagnosed at Barretos 
Cancer Hospital (Barretos, SP, Brazil) between June 2000 
and August 2010, were evaluated and the clinical data are 
summarized in Table I. The mean age of the patients was 
55.9 years (range, 27‑86 years). KRAS and BRAF mutation 
status data were retrieved from our previous study (24), 
while HPV16 and HPV18 status, and β-globin, p16, Ki-67, 
minichromosome maintenance protein complex (MCM) and 
topoisomerase II α (TOP2A) expression immunohistochemical 
analyses were retrieved from another previous study (25) and 
are summarized in Table II. All patients included in the present 
study provided written informed consent, and the study was 
approved by the Barretos Cancer Hospital Ethical Committee 
(Barretos, SP, Brazil) approval under the protocol number 
310/2010. The data of all patients alive by December 2012 
were censored.
Samples, fixed for 24 h at room temperature in 10% buff-
ered formalin and embedded in paraffin blocks, were retrieved 
from the Department of Pathology of Barretos Cancer 
Hospital. Subsequently, 5‑µm‑thick sections were placed on 
histological slides, and hematoxylin and eosin staining (1 min 
in hematoxylin and 30 sec in eosin at room temperature) 
was performed to confirm the initial diagnosis using a light 
microscope (magnification, x400).
Immunohistochemistry. Sections (5‑µm thick) were 
subjected to immunohistochemical staining according 
to the streptavidin-biotin peroxidase method using an 
UltraVision Large Volume Detection system Anti-Polyvalent, 
HRP kit (cat. no. TP‑125‑HL; LabVision; Thermo Fisher 
Scientific, Inc., Waltham, MA, USA). Briefly, slides were 
xylene‑deparaffinized and rehydrated in a descending alcohol 
series (100, 90, 70 and 50%, followed by water), prior to 
antigen‑retrieval for 20 min at 98˚C in 10 mM citrate buffer 
(pH=6.0; Sigma‑Aldrich; Merck KGaA, Darmstadt, Germany). 
Endogenous peroxidase blocking was performed by incubation 
with hydrogen peroxide (3% in methanol v/v; Sigma-Aldrich; 
Merck KGaA) for 10 min at room temperature. Protein blocking 
was performed for 5 min with UV Block Plus (LabVision; 
Thermo Fisher Scientific, Inc.). Subsequently, the slides were 
incubated with a polyclonal primary anti-RKIP antibody (dilu-
tion, 1:1,000; cat. no. 07‑137; Upstate Biotechnology, Inc., Lake 
Placid, NY, USA) for 60 min at room temperature, followed by 
a secondary biotinylated goat anti-polyvalent antibody (part of 
the aforementioned kit) for 5 min at room temperature, after 
which they were incubated with the streptavidin-peroxidase 
complex for 5 min (LabVision; Thermo Fisher Scientific, 
Inc.) at room temperature. Chromogen color development 
was accomplished with 3,3'-diaminobenzidine (5 min at room 
temperature) and a Gill-2 hematoxylin counterstain (30 sec at 
room temperature).
The slides were scored in a blinded manner by one pathol-
ogist and one histologist using semi-quantitative criteria, 
as previously described (18,26) using a light microscope 
(magnification, x400). The labeling score was determined as 
the sum of the percentage of positive cells (0, negative; 1, <5% 
immunoreactive cells; 2, 5‑50% immunoreactive cells; 3, >51% 
immunoreactive cells) and the labeling intensity (0, negative; 
1, weak; 2, moderate; 3, strong) in the tumor tissue. RKIP 
expression was classified as low (scores between 0 and 4) 
or high (scores 5 and 6). This scoring system was used to 
compare strongly positive RKIP samples vs. samples with 
weak/moderate expression. Normal stomach sections 
expressing RKIP were used as a positive control (19).
Statistical analysis. Analysis of descriptive characteristics was 
performed to characterize the study population using SPSS 
statistical software (version 21; IBM Corp., Armonk, NY, 
USA). Comparisons between groups were performed using 
Fisher's exact tests and the Kaplan‑Meier method was applied 
to assess survival rates, using a log-rank test to compare 
the curves. P<0.05 was considered to indicate a statistically 
significant difference.
Results
Patient characteristics and survival analysis. Follow‑up was 
performed every 6 months or as necessary (until the point of 
mortality), with a mean follow‑up time of 57.2 months (range, 
2.1‑158.4 months). From the 48 cases, 8 were diagnosed with 
HSIL, 14 were diagnosed with adenocarcinomas and 26 were 
diagnosed with SCC. Log‑rank analysis revealed a lower 
5‑year survival rate for patients with adenocarcinoma (40.8%), 
compared with for those with SCC and HSIL (76.7 and 80%, 
respectively; P=0.0479; Fig. 1A). No significant difference 
was observed in the disease-free survival rates between the 
three tumor types (P=0.201; Fig. 1B). There was no significant 
difference in the overall survival of patients based on clinical 
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stage (Fig. 1C), but clinical stages III/IV were associated with a 
poorer disease-free survival rate (a 5-year disease-free survival 
rate of 37.3% vs. 62.5 and 82.6% for clinical stages 0 and I/II, 
respectively; P<0.01; Fig. 1D). Additionally, older patients 
(≥67 years old) were revealed to experience a poorer 5‑year 
survival rate [41.7 vs. 80.2 and 74.5% for young‑(≤46 years 
old) and medium-age patients (47-66 years old), respectively; 
P=0.085, Fig. 1E], although there was no significant difference 
in disease-free survival (Fig. 1F).
Immunohistochemistry findings. Table I presents the clinico-
pathological features of the patients as associated with RKIP 
expression. High RKIP expression was associated with 
non‑Caucasian patients (37.5 vs. 7.5% in Caucasians; P=0.019) 
and younger (≤46 years old) patients (33.3 vs. 0.0% of older 
patients; P=0.047). Additionally, high RKIP expression was 
associated with lower tumor clinical stages (50% in stage 0 vs. 
6.7% in stages III/IV; P=0.038). Finally, anal HSILs (37.5%) 
exhibited the greatest percentage of high RKIP expression, 
followed by anal SCCs (11.5%) and adenocarcinomas (0.0%) 
(P=0.037; Table I, Fig. 2). There was no significant difference 
in overall- or disease-free survival between RKIP-high and 
RKIP-low expressing patients (Fig. 3A and B). Similarly, 
following the stratification of patients by tumor type (HSIL 
and SCC), there was no significant difference in survival based 
on RKIP expression (Fig. 3C and D). All the patients with 
adenocarcinoma demonstrated low tumor RKIP expression.
RKIP expression was correlated with HPV16 infection, 
KRAS and BRAF mutation status, and the expression of 
β-globin, p16, Ki-67, MCM and TOP2A, as detected by immu-
nohistochemistry. There were no positive cases of HPV18. All 
30 cases that were analyzed for KRAS mutation were wild 
type, and only 1 case of the 35 analyzed was positive for a 
BRAF V600E mutation. A decreased percentage of HPV16+ 
Table I. Clinicopathological characteristics of the patients and association with RKIP expression.
Parameter n Low RKIP, n (%) High RKIP, n (%) P‑value
Sex    0.999
  Female 27 24 (88.9) 3 (11.1)
  Male 21 18 (85.7) 3 (14.3)
Ethnicity    0.019a
  Caucasian 40 37 (92.5) 3 (7.5)
  Non‑caucasian 8 5 (62.5) 3 (37.5)
Age, years    0.047a
  ≤46 12 8 (66.7) 4 (33.3)
  47‑66 24 22 (91.7) 2 (8.3)
  ≥67 12 12 (100) 0 (0.0)
Tobacco consumption    0.665
  No 23 19 (82.6) 4 (17.4)
  Yes (current or past) 22 20 (90.9) 2 (9.1)
Clinical grade    0.038a
  Stage 0 6 3 (50) 3 (50)
  Stages I and II 24 22 (91.7) 2 (8.3)
  Stages III and IV 15 14 (93.3) 1 (6.7)
Histological type    0.037a
  SCC 26 23 (88.5) 3 (11.5)
  Adenocarcinoma 14 14 (100) 0
  HSIL 8 5 (62.5) 3 (37.5)
Clinical response    0.847
  No evidence 24 20 (83.3) 4 (16.7)
  Complete 12 11 (91.7) 1 (8.3)
  Progression 7 6 (85.7) 1 (14.3)
Status    0.743
  Deceased (by cancer) 13 12 (92.3) 1 (7.7)
  Deceased (not by cancer) 4 4 (100.0) 0 (0.0)
  Alive without disease 26 21 (80.8) 5 (19.2)
  Alive with disease 5 5 (100.0) 0 (0.0)
Where data is missing regarding certain patients, it will not available from the patient medical records. aP<0.05. SCC, squamous cell carcinoma; 
HSIL, high‑grade squamous intra‑epithelial lesions; RKIP, Raf kinase inhibitor protein. 
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cases were identified with high expression of RKIP, compared 
with the HPV16- cases (5.3 vs. 40%; P=0.013; Table II), indi-
cating a possible correlation between HPV16 infection and 
RKIP expression.
Discussion
A number of previous studies have demonstrated that RKIP 
expression has prognostic value in several tumor types, 
including gastric, colorectal and gastrointestinal stromal 
tumors (17-19). However, other studies have identified a number 
of molecular distinctions between anal canal tumors and their 
colorectal counterparts (24,27). Therefore, the present study 
aimed to evaluate RKIP expression in invasive and in situ 
tumors of the anal canal, and to correlate findings with the 
clinicopathological data.
The results of the present study revealed a poorer overall 
survival rate in patients diagnosed with adenocarcinoma, 
compared with in those diagnosed with SCC or HSIL. An 
improved prognosis was expected in patients with HSIL, 
considering that these in situ lesions are associated with <30% 
recurrence following treatment (5,28). Additionally, the results 
of the present study demonstrated an improved survival rate 
in patients with SCC, compared with in patients with adeno-
carcinoma. This supports the findings of a previous study 
that compared the overall survival and prognosis of patients 
with anal adenocarcinoma, SCC and rectal adenocarcinoma, 
in which the authors demonstrated a poorer overall survival 
Figure 1. Survival curves based on the various clinicopathological features 
of patients with anal cancer. (A) Overall survival and (B) disease‑free 
survival of patients with HSIL, adenoca and SCC. (C) Overall survival and 
(D) disease‑free survival based on clinical stage. (E) Overall survival and 
(F) disease‑free survival based on patient age at diagnosis. HSIL, high‑grade 
squamous intra-epithelial lesion; SCC, squamous-cell carcinoma; adenoca, 
adenocarcinoma; y.o., years old.
Figure 2. (A‑C) Immunohistochemical analysis of RKIP in anal cancer 
samples. (A) High expression in high‑grade squamous intra‑epithelial lesions 
(magnification, x400). (B) High expression in squamous‑cell carcinomas 
(magnification, x400). (C) Low expression in adenocarcinomas (magnifica-
tion, x400). (D) High expression in normal stomach tissues, which were used 
as positive controls (magnification, x400). RKIP, Raf kinase inhibitor protein.
Table II. Pathological characteristics of the patients and 
association with RKIP expression.
  Low RKIP  High RKIP  
Parameter n labeling, n (%) labeling, n (%) P‑value
HPV16    0.013b
  Negative 10   6 (60.0)   4 (40.0) 
  Positive 38 36 (94.7) 2 (5.3) 
β-globina    0.999
  Weak 3     3 (100.0) 0 (0.0) 
  Strong 45 39 (86.7)   6 (13.3) 
p16a    0.999
  Negative 13 11 (84.6) 2 (15.4) 
  Positive 34 30 (88.2) 4 (11.8) 
  NA 1 NA NA 
Ki-67a    0.637
  1+2+3+ 12 10 (83.3) 2 (16.7) 
  4+ 35 31 (88.6) 4 (11.4) 
  NA 1 NA NA 
MCMa    0.999
  Negative 9   8 (88.9) 1 (11.1) 
  Positive 39 34 (87.2) 5 (12.8) 
TOP2Aa    0.329
  1+2+ 32 27 (90.0) 3 (10.0) 
  3+ 12 9 (75.0) 3 (25.0) 
  NA 4 NA  NA
aImmunohistochemical values acquired from reference (25). bP<0.05. 
NA, not available; HPV, human papillomavirus; MCM, minichromo-
some maintenance protein complex; TOP2A, topoisomerase II α; 
RKIP, Raf kinase inhibitor protein.
ONCOLOGY LETTERS  16:  1785-1790,  2018 1789
rate and prognosis for patients with anal adenocarcinoma (28). 
This same trend was described by our group in a previous 
study (24). Furthermore, when considering patient age, the 
present study identified poorer survival rates in patients 
≥67 years old compared with in younger patients (≤47 years 
old), supporting the results presented by a prior study that 
revealed younger patients experienced improved overall- and 
disease-free survival rates compared with older patients with 
anal cancer (29). In addition, the present study did not identify 
high RKIP expression in the tumors of any older patients.
RKIP is considered a tumor suppressor gene, and its 
expression may prevent RAF/MEK/ERK signal transduc-
tion (30), thus serving a function in the inhibition of cancer 
development. The present study identified an increased 
percentage of high RKIP expression in patients with in situ 
lesions (HSIL) than in patients with invasive lesions (SCC 
and adenocarcinoma). Notably, an increased percentage of 
patients at clinical stage 0 exhibited high RKIP expression, 
compared with patients with higher clinical stages (I/II or 
III/IV). Considering the patient stratification was dependent 
on RKIP expression, the lack of receiver operating char-
acteristic analysis may be a limitation of the present study; 
however, an RKIP scoring system was used according to our 
previously published studies (26), a method that is widely used 
for the assessment of immunohistochemistry staining (31), and 
allowed for inter‑study comparisons.
Infection with high-r isk HPV (HR-HPV16 and 
HR-HPV18) is considered the major risk factor for anal 
cancer development (4). Additionally, a previous study 
demonstrated that HPV-/p16- patients experienced poorer 
outcomes compared with HPV+/p16+ patients (20). Another 
study revealed the relevance of p16 expression, reporting an 
association with improved overall- and disease-free survival 
rates (6); however, the results of the present study did not 
identify any correlation between the expression of RKIP and 
of p16, which may explain the lack of correlation between 
RKIP expression and survival. In the cohort of the present 
study, a decreased number proportion of HPV16+ patients 
exhibited high RKIP protein expression compared with 
HPV16- patients. Hu et al (32) analyzed RKIP expression 
via immunohistochemical analysis in normal and cancerous 
cervical tissues and revealed high RKIP expression in 
normal tissue, low expression in primary cancer and the 
lowest (or absent) levels of expression in metastatic disease. 
Considering that HR-HPV infection is a fundamental step for 
cervical cancer development (9,10), there may be an inverse 
association between HR-HPV infection and RKIP expres-
sion, as was observed in the present study cohort. However, 
more studies are required in order to elucidate the molecular 
basis of this finding.
In conclusion, to the best of our knowledge, this is the 
first study to investigate RKIP expression levels in a set of 
anal tumors. The results of the present study demonstrated 
that high RKIP expression is present in lesions with clinical 
features that are generally associated with a good prognosis, 
including lower age at diagnosis, in situ lesions and lesions 
Figure 3. Survival curves based on RKIP expression groups in anal cancer samples. (A) Overall survival and (B) disease‑free survival based on the RKIP 
expression in all samples. (C) Overall survival of patients with HSIL based on RKIP expression. (D) Overall survival of patients with SCC based on RKIP 
expression. RKIP, Raf kinase inhibitor protein.
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of a lower clinical grade, and that HPV16 infection may 
affect RKIP expression; a finding that requires further 
investigation.
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